We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look ...

We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to ...

Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Arrowstreet Capital Limited Partnership decreased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 99.1% during the 4th quarter, according to the company in its most recent filing ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic tariffs.

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Copyright 2025 The Associated Press. All Rights Reserved. This image provided by Eli Lilly shows the company’s new ...